MIRAMAR, Fla.--(Quintiles Prime Site, a distinction that gives Comprehensive an enhanced role in global clinical research and testing of new and more effective medicines.)--Comprehensive Clinical Development (Comprehensive), a strategic clinical research company providing site services for Phase l through IV clinical trials, today announced recent designation as a
“We are honored to be recognized as a Prime Site and continue growing our longstanding relationship with Quintiles”
As a Quintiles Prime Site, Comprehensive has the opportunity to be first in line for access to new industry-sponsored clinical trials available through Quintiles. Comprehensive joins a select group of organizations across North and South America, Europe, Africa and Asia, and is the first non-academic, non-hospital based organization awarded this status.
Comprehensive was selected because of its deep experience in delivering high-quality data, rapid study start-up expertise and its access to substantial patient populations across multiple therapeutic areas, including psychiatry, oncology, neurology and endocrinology. Comprehensive will also provide access to research participants through its well-established group of sites and therapeutic networks.
“We are honored to be recognized as a Prime Site and continue growing our longstanding relationship with Quintiles,” said Jack McGovern, CEO, Comprehensive. “We look forward to sharing in their continued success as we address the industry’s demand to streamline clinical research and provide new drugs to patients faster.”
"Comprehensive’s dedication to timeliness and quality, combined with their strong patient relationships and delivery quality, will enhance our ability to recruit patients quickly and efficiently to provide greater value for our customers,” said Lindy Jones, Senior Vice President, Integrated Site Services, Quintiles. “We look forward to a successful relationship with Comprehensive.”
About Comprehensive Clinical Development
Comprehensive Clinical Development is a strategic clinical research partner providing a full range of clinical services in a broad range of therapeutic areas through its clinical pharmacology units, CNS investigator sites and therapeutic networks. Comprehensive maintains an outstanding record for consistently delivering quality and success on time and within budget. As a leader in the field of Phase I clinical pharmacology, Comprehensive holds a solid track record of collecting early safety and efficacy data across both healthy and specialty populations and offers distinct capabilities in clinical research. The Comprehensive CNS investigator sites have participated in the development of every major psychiatric drug approved during the last eight years.
For more information about Comprehensive Clinical Development, visit www.ComprehensiveCD.com.
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. Our network of more than 25,000 professionals in 60 countries has an eye on the future while delivering results today with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies develop and commercialize products to improve and lengthen patients’ lives while demonstrating value to stakeholders. Visit www.quintiles.com for more information and www.quintiles.com/news for additional company news.